22q11.2 deletion syndrome as a natural model for COMT haploinsufficiency- related dopaminergic dysfunction in ADHD

International Journal of Neuropsychopharmacology

Volumn 10, Issue 3, 2007, Pages 295-299

  Fallgatter, Andreas J ^a   Lesch, Klaus Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE;

AMINO ACID SUBSTITUTION; ATTENTION DEFICIT DISORDER; CHROMOSOME 22Q; CHROMOSOME DELETION; COMORBIDITY; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; VELOCARDIOFACIAL SYNDROME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; CHILD; DOPAMINE; HAPLOTYPES; HUMANS; PREFRONTAL CORTEX; SEQUENCE DELETION;

EID: 34247874519     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006985     Document Type: Review

References (45)

1. Almasy L, Blangero J (2001). Endophenotypes as quantitative risk factors for psychiatric disease: rationale and study design. American Journal of Medical Genetics 105, 42-44.
2. Antshel KM, Conchelos J, Lanzetta G, Fremont W, Kates WR (2005). Behavior and corpus callosum morphology relationships in velocardiofacial syndrome (22q11.2 deletion syndrome). Psychiatry Research 138, 235-245.
3. Barr CL, Wigg K, Malone M, Schachar R, Tannock R, Roberts W, Kennedy JL (1999). Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. American Journal of Medical Genetics 88, 710-713.
4. Bearden CE, Jawad AF, Lynch DR, Sokol S, Kanes SJ, McDonald-McGinn DM, Saitta SC, Harris SE, Moss E, Wang PP, et al. (2004). Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. American Journal of Psychiatry 161, 1700-1702.
5. Bellgrove MA, Domschke K, Hawi Z, Kirley A, Mullins C, Robertson IH, Gill M (2005). The methionine allele of the COMT polymorphism impairs prefrontal cognition in children and adolescents with ADHD. Experimental Brain Research 163, 352-360.
6. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer JP, et al. (2002). Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry 52, 701-707.
7. Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, Kolachana BS, Egan MF, Goldberg TE, Weinberger DR (2005). Effect of catechol-O-methyltransferase val158met genotype on attentional control. Journal of Neuroscience 25, 5038-5045.
8. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, Wavrant-De Vrieze F, et al. (2005). Support for association between ADHD and two candidate genes: NET1 and DRD1. American Journal of Medical Genetics. B: Neuropsychiatric Genetics 134, 67-72.
9. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM (2003). A population-based study of the 22q11.2 deletion: phenotype, incidence and contribution to major birth defects in the population. Pediatrics 112, 101-107.
10. Castellanos FX, Tannock R (2002). Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nature Reviews Neuroscience 3, 617-628.
11. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. (2004). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. American Journal of Human Genetics 75, 807-821.
12. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG (2005). Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. Journal of Cognitive Neuroscience 17, 1018-1025.
13. Diamond A, Briand L, Fossella J, Gehlbach L (2004). Genetic and neurochemical modulation of prefrontal cognitive functions in children. American Journal of Psychiatry 161, 125-132.
14. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences USA 98, 6917-6922.
15. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I, Nemanov L, Ebstein RP (1999). Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. American Journal of Medical Genetics 88, 497-502.
16. Fallgatter AJ, Ehlis A-C, Seifert J, Strik WK, Scheuerpflug P, Zillessen K, Herrmann MJ, Warnke A (2004). Altered response control and anterior cingulate function in ADHD boys. Clinical Neurophysiology 115, 973-981.
17. Fallgatter AJ, Ehlis A-C, Rösler M, Strik WK, Blocher D, Herrmann MJ (2005). Diminished prefrontal brain function in adults with attention deficit hyperactivity disorder (ADHD) related psychopathology in childhood. Psychiatry Research: Neuroimaging 138, 157-169.
18. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proceedings of the National Academy of Sciences USA 95, 9991-9996.
19. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Archives of General Psychiatry 60, 889-896.
20. Goldberg TE, Weinberger DR (2004). Genes and the parsing of cognitive processes. Trends in Cognitive Science 8, 325-335.
21. Goldman-Rakic PS, Muly 3rd EC, Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Research. Brain Research Reviews 31, 295-301.
22. Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A (2003). Methylphenidate treatment with velocardiofacial syndrome: an open-label study. Journal of Clinical Psychiatry 64, 1163-1169.
23. 158Met allele with ADHD and OCD subjects with velocardiofacial syndrome. International Journal of Neuropsychopharmacology. doi:10.1017/S1461145706006699. Published online: 31 May 2006.
24. Gothelf D, Presburger G, Levy D, Nahmani A, Burg M, Berant M, Blieden LC, Finkelstein Y, Frisch A, Apter A, Weizman A (2004). Genetic, developmental, and physical factors associated with attention deficit hyperactivity disorder in patients with velocardiofacial syndrome. American Journal of Medical Genetics. B Neuropsychiatric Genetics 126, 116-121.
25. Grossman MH, Emanuel BS, Budarf ML (1992). Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 12, 822-825.
26. Hawi Z, Millar N, Daly G, Fitzgerald M, Gill M (2000). No association between catechol-O-methyltransferase (COMT) gene polymorphism and attention deficit hyperactivity disorder (ADHD) in an Irish sample. American Journal of Medical Genetics 96, 282-284.
27. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160, 13-23.
28. Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N, Waldman I, Fitzgerald M, Gill M (2002). Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 27, 607-619.
29. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6, 243-250.
30. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J (1995). Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202-4210.
31. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D (2002). A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. American Journal of Psychiatry 159, 652-654.
32. Manor I, Kotler M, Sever Y, Eisenberg J, Cohen H, Ebstein RP, Tyano S (2000). Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. American Journal of Medical Genetics 96, 858-860.
33. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proceedings of the National Academy of Sciences USA 100, 6186-6191.
34. Murphy KC (2005). Annotation: velo-cardio-facial syndrome. Journal of Child Psychology and Psychiatry 46, 563-571.
35. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C (2002). Chromosome 22q11 deletion syndrome (CATCH 22): neuropsychiatric and neuropsychological aspects. Developmental Medicine & Child Neurology 44, 44-50.
36. Palmatier MA, Kang AM, Kidd KK (1999). Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biological Psychiatry 46, 557-567.
37. Payton A, Holmes J, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, Harrington R, McGuffin P, O'Donovan M, Owen M, et al. (2001). Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study. American Journal of Medical Genetics 105, 464-470.
38. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV (2003). Family-based and case-control association studies of catechol-O- methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. American Journal of Medical Genetics. B Neuropsychiatric Genetics 118, 103-109.
39. Reif A, Fallgatter AJ, Ehlis A-C, Lesch KP (2004). Altered cingulate functioning in two cases of chromosome 22q11 deletion syndrome. Psychiatry Research: Neuroimaging 132, 273-278.
40. Reuter M, Hennig J (2005). Association of the functional catechol-O-methyltransferase VAL158MET polymorphism with the personality trait of extraversion. Neuroreport 16, 1135-1138.
41. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
42. Shprintzen RJ (2000). Velo-cardio-facial syndrome: a distinctive behavioral phenotype. Mental Retardation and Developmental Disabilities Research Reviews 6, 142-147.
43. Sonuga-Barke EJ (2002). Psychological heterogeneity in AD/HD - a dual pathway model of behaviour and cognition. Behavioral Brain Research 130, 29-36.
44. Turic D, Williams H, Langley K, Owen M, Thapar A, O'Donovan MC (2005). A family based study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD). American Journal of Medical Genetics. B Neuropsychiatric Genetics 133, 64-67.
45. Wolraich ML, Doffing MA (2004). Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18, 243-250.